Skip to content
10-K

Annual Report

Aligos Therapeutics, Inc. ALGS

0000950170-25-035929

← back to feed
Filed
Mar 10, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Capex FY 2024 · Dec 31, 2024 $130K
Capex FY 2024 · Dec 31, 2023 $19K
Shares Diluted restated FY 2024 · Dec 31, 2023 2.56M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$79M
Cash And Equivalents FY 2024 · Dec 31, 2023 $135.7M
Current Liabilities FY 2024 · Dec 31, 2023 $23.91M
Total Liabilities FY 2024 · Dec 31, 2023 $59.45M
Current Assets FY 2024 · Dec 31, 2023 $141.08M
Total Assets FY 2024 · Dec 31, 2023 $151.53M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$34.20
Eps Basic restated FY 2024 · Dec 31, 2023 −$34.20
Sga Expense FY 2024 · Dec 31, 2023 $30.62M
Rd Expense FY 2024 · Dec 31, 2023 $73.04M
Net Income FY 2024 · Dec 31, 2023 −$87.68M
Operating Income FY 2024 · Dec 31, 2023 −$88.13M
Revenue FY 2024 · Dec 31, 2023 $6.19M
Stockholders Equity FY 2024 · Dec 31, 2022 $103.9M